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Background: A susceptibility locus, Nidd2n, for type 2 diabetes has been mapped to mouse chromosome 14 (Chr
14) and confirmed using the consomic strain (C3H-Chr 14NSY) of the Nagoya-Shibata-Yasuda (NSY) mouse, an animal
model of spontaneous type 2 diabetes. The aim of this study was to localize and characterize Nidd2n.
Results: We constructed two novel congenic strains homozygous for different segments of NSY-Chr 14 on the control
C3H/HeNcrj (C3H) background: R1 (C3H.NSY-(D14Mit206-D14Mit5)) possesses the proximal and middle segment, and R2
(C3H.NSY-(D14Mit206-D14Mit186)) possesses the most proximal segment of NSY-Chr 14. Diabetes-related phenotypes
were studied in comparison with those of consomic C3H-Chr 14NSY (R0) and parental NSY and C3H strains. Congenic
R1 and R2 showed significantly higher post-challenge glucose than that in C3H mice. Fasting glucose, in contrast, was
significantly lower in R1 and R2 than in C3H mice. Insulin sensitivity was significantly impaired in R1 and R2 compared
to C3H mice. R2 showed significantly higher body weight and fat-pad weight than those in C3H and R1. Leptin level
was significantly higher in R0, R1 and R2 than in C3H mice, with R2 showing the highest level, similar to that in NSY
mice. Serum adiponectin level was significantly lower in R0, R1 and R2 than in C3H mice, while it was significantly
higher in NSY than in C3H mice.
Conclusions: These data indicate that Chr 14 harbors multiple genes for diabetes-related phenotypes. The original
Nidd2n, which is located in the middle region of Chr 14, was divided into two segments; Nidd2.1n in proximal Chr 14
and Nidd2.2n in distal Chr 14. Nidd2.1n contributes to post-challenge hyperglycemia, insulin resistance and adiposity.
Nidd2.2n contributes to fasting as well as post-challenge hyperglycemia and insulin resistance. Adp1n, which
contributes to decreased adiposity and increased insulin sensitivity, rather than a diabetogenic gene, was
mapped in the middle segment.
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Diabetes and obesity are multifactorial diseases caused
by a complex interaction of environmental and genetic
factors, with the latter consisting of multiple susceptibility
genes, making it difficult to clarify their functions and
interactions in conferring susceptibility to diabetes and
obesity in humans. Recent genome-wide association
studies (GWAS) have identified a large number of single* Correspondence: ikegami@med.kindai.ac.jp
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unless otherwise stated.nucleotide polymorphisms associated with diabetes and
obesity [1], but identification of the causal variants in
these loci is a formidable challenge. Inbred animal
models of diabetes and obesity are therefore invaluable to
decipher the complexity of human diabetes and obesity, as
evidenced by the identification of common functional
variants of a gene involved in type 1 diabetes susceptibility
in both humans and mice [2].
The Nagoya-Shibata-Yasuda (NSY) mouse was established
as an inbred animal model with spontaneous development
of type 2 diabetes by selective breeding for glucose intoler-
ance from a closed colony of Jcl:ICR mice [3-5]. The NSYLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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2 diabetes in that the onset is age-dependent, the disease
is associated with moderate obesity with abdominal fat
accumulation, and both impaired insulin response to
glucose and insulin resistance contribute to the disease
development [4,5].
Using an F2 cross of the NSY and control C3H/HeNcrj
(C3H) strains, we previously mapped three major quanti-
tative trait loci (QTLs) affecting diabetes-related pheno-
types (Nidd1n, Nidd2n and Nidd3n on Chr 11, 14 and 6,
respectively) [6], a QTL for fatty liver (Fl1n on Chr 6) and
a QTL for body weight (Bw1n on Chr 7) [7]. To obtain
direct evidence that Nidd2n on Chr 14 confers susceptibil-
ity to diabetes, we constructed consomic C3H-Chr 14NSY
mice, in which the NSY-derived whole Chr 14 was intro-
gressed onto the genetic background of control C3H mice
[8], because the regions showing significant linkage with
Nidd2n were broad (peak region near D14Mit5) [6].
C3H-Chr 14NSY mice showed significantly higher blood
glucose levels than those in C3H mice, indicating that
Chr 14 harbors a locus for hyperglycemia. C3H-Chr
14NSY mice showed significantly impaired insulin sensi-
tivity, but normal insulin secretion, indicating that the
main effect was due to insulin resistance [8]. Body
weight was not increased by introgression of NSY-Chr 14
alone, but did increase in the presence of NSY-Chr11,
indicating a genetic interaction between Chr 14 and Chr
11 for obesity [8]. The region on mouse Chr 14 is syn-
tenic to human Chr 3p, 8p, 10q, 13q, and 14q, and sev-
eral whole genome studies have mapped loci associated
with diabetes [9-12] and obesity [13] to the corresponding
regions. Although Nidd2n has a broad peak in the odds
curve, the nearest marker of the peak region is D14Mit5
[6] on the C3 region of the chromosomal band, which is
syntenic to human 13q12. Many genome-wide association
studies have revealed several candidate genes for type 2
diabetes [1], although the orthologues of these genes are
not located near Nidd2n or on Chr 14. Identification and
characterization of the function of Nidd2n on mouse
Chr 14 are expected to contribute to identification and
characterization of diabetogenic genes in humans.
The present study was performed to localize and
characterize the function of Nidd2n on mouse Chr 14.
To this end, we constructed two novel congenic strains
homozygous for different segments of NSY-Chr 14 and
investigated diabetes-related phenotypes in these mice
in comparison with those of the original consomic
C3H-Chr 14NSY and parental NSY and C3H strains.
Methods
Animals
The consomic strain, C3H-Chr 14NSY (R0), homozygous
for NSY-derived whole Chr 14 on the control C3H/HeNcrj
(C3H) background, was previously established in the N8F1generation using the speed congenic method [8]. Congenic
lines were produced by mating (R0 x C3H) F1 with C3H
and selecting males that possessed the genomic region
of interest on Chr 14 using 9 microsatellite markers
(Additional file 1: Table S1). For the background gen-
ome, we used 69 microsatellite markers (Additional file 1:
Table S1) spanning the whole mouse genome except for
Chr 14, and confirmed the markers derived from C3H, as
described previously [8,14]. These male mice were mated
with female C3H mice, and their progeny with the genomic
region of interest were intercrossed to obtain homozygotes.
These lines were maintained by brother-sister mating.
Mice were maintained under specific pathogen-free (SPF)
conditions in the animal facilities of Osaka University
Graduate School of Medicine. All mice had free access
to tap water and a standard diet (CRF-1: Oriental Yeast,
Tokyo, Japan) in an air-conditioned room (22–25°C)
with a 12-h light–dark cycle (6:00–18:00 h). Mice were
housed in PC7115HT cages, 189 mm × 297 mm × 128 mm
(Allentown Inc., New Jersey, USA), at 6 or fewer mice
per cage. The animal protocols used for this study were
approved by the Osaka University Graduate School of
Medicine Committee on Animal Welfare (Approval num-
ber: 030038–444).
Phenotypic analyses
Glucose tolerance and body weight were monitored at
24 weeks of age. Glucose tolerance was assessed by intra-
peritoneal glucose tolerance test (ipGTT) (2 g glucose/kg
body weight) in overnight-fasted mice, and blood glucose
levels were measured at 0, 30, 60, 90, and 120 min. The
area under the glucose concentration curve (gAUC) was
calculated according to the trapezoid rule from the glucose
measurements at baseline (0 min), 30, 60, 90, and 120 min.
Insulin tolerance test (ITT) was performed by injecting
human insulin (0.25 IU/kg body weight) intraperitoneally
in overnight-fasted mice at 26 weeks of age, and blood
glucose levels were measured at 0, 15, 30, 45, and 60 min.
Results are expressed as the % decrease in glucose area
from the baseline.
Insulin secretion in response to glucose was assessed by
ipGTT (2 g glucose/kg body weight) in overnight-fasted
mice at 28 weeks of age, and blood glucose and serum in-
sulin levels were measured at 0, 15, and 30 min. Incre-
mental AUC of insulin (ΣΔiAUC) and glucose (ΣΔgAUC)
were calculated according to the trapezoid rule from the
insulin and glucose measurements at baseline (0 min), 15,
and 30 min. The insulinogenic index was calculated as
ΣΔiAUC ÷ ΣΔgAUC.
Anatomical phenotypes were studied at 30 weeks of
age. Under anaesthesia with pentobarbital (Dainippon,
Osaka, Japan), body weight and anal-nasal length were
measured. BMI was calculated as body weight in g divided
by the square of anal–nasal length in cm. Mice were killed
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enteric and retroperitoneal fat pads were dissected out
and weighed.
Blood sample assays
Blood glucose level was determined by the glucose oxidase
method using Glutest Ace (Sanwa Kagaku Kenkyusho Co.,
Ltd., Nagoya, Japan). Plasma insulin level was measured
by ELISA (Morinaga, Yokohama, Japan). Insulin values in
micrograms per liter obtained by ELISA were converted
to picomoles per liter by multiplying by 174. Serum leptin
and adiponectin were measured at 30 weeks of age with
an ELISA-based leptin assay (TECHNE, Minneapolis,
USA) and adiponectin assay (Otsuka Pharmaceutical
Co., Ltd., Tokyo, Japan), according to the manufacturers’
instructions.
Statistical analysis
All results are expressed as mean ± SEM. Statistical
analysis was performed by unpaired t-test. Correlations
between leptin and fat-pad weight and between adipo-
nectin and fat-pad weight were examined with the
Pearson correlation coefficient. A value of p <0.05 was
regarded as significant.
Results
Establishment of new congenic strains
We produced two novel congenic strains, which possessed

















Figure 1 Schematic illustration of chromosome 14 of consomic mice (R
D14Mit5)), R2 (C3H.NSY-(D14Mit206-D14Mit186))), which carry NSY-deriv
Regions from NSY mice are shown in gray, and regions from C3H mice are sh
polymorphisms from the centromere shown in parentheses (cM) were obtaincongenic strain R1 (C3H.NSY-(D14Mit206-D14Mit5))
possessed the proximal and middle segment of NSY-Chr
14 from the centromere to the recombinant position
between D14Mit5 and D14Mit235. The other congenic
strain R2 (C3H.NSY-(D14Mit206-D14Mit186)) possessed
the proximal segment of NSY-Chr 14 from the centro-
mere to the recombinant position between D14Mit186
and D14Mit59.
Phenotypic analysis of consomic C3H-Chr 14NSY; R0
R0 mice exhibited significantly higher blood glucose levels
after fasting (p < 0.01) and at all time points after a glu-
cose challenge (p < 0.001) than those in C3H mice
(Figure 2A). The insulinogenic index in R0 mice was
similar to that in C3H mice, and was significantly
higher than that in NSY mice (p < 0.05) (Figure 2E). The
glucose-lowering effect of insulin was significantly im-
paired in R0 compared with that in C3H mice (p < 0.001)
(Figure 2F). No significant difference was observed in
body weight and BMI between R0 and C3H mice (Table 1).
Fat-pad weight and the percentage of fat-pad weight/body
weight were significantly elevated in R0 compared with
those in C3H mice (p < 0.01).
Phenotypic analysis of congenic R1 mice
Fasting glucose in R1 mice was slightly, but signifi-
cantly lower than that in control C3H mice (p < 0.05)
(Figure 2B, C). In contrast, glucose levels at all time



























0 (C3H-Chr 14NSY)) and congenic mice (R1 (C3H.NSY-(D14Mit206-
ed susceptible regions on a C3H-derived resistance background.
own in white. The map positions of simple sequence length




















































Figure 2 Diabetes-related phenotypes in NSY, C3H, C3H-Chr 14NSY (R0), C3H.NSY-(D14Mit206-D14Mit5) (R1) and C3H.NSY-(D14Mit206-
D14Mit186) (R2) mice. A. Blood glucose levels during ipGTT in NSY (n = 16; ▲), C3H (n = 39; □) and R0 mice (n = 36; ■). B. Blood glucose levels
during ipGTT in C3H (n = 39; □), R0 (n = 36; ■), R1 (n = 23; ◆) and R2 mice (n = 23; ◇). C. Fasting glucose level in NSY (n = 16), C3H (n = 39), R0
(n = 36), R1 (n = 23) and R2 mice (n = 23). D. Area under glucose concentration curve (gAUC) during ipGTT in NSY (n = 16), C3H (n = 39), R0
(n = 36), R1 (n = 23) and R2 mice (n = 23). E. Insulinogenic index in NSY (n = 20), C3H (n = 21), R0 (n = 15), R1 (n = 20) and R2 mice (n = 16).
F. Insulin resistance assessed by decrease in glucose area in insulin tolerance test in NSY (n = 18), C3H (n = 18), R0 (n = 19), R1 (n = 23) and R2
mice (n = 22). *p < 0.05, **p < 0.01, ***p < 0.001 vs. C3H. †p < 0.05, ††p < 0.01, †††p < 0.001 vs. R0.
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in R1 mice, as assessed by AUC during ipGTT, was sig-
nificantly more severe than that in C3H mice, but was
not as severe as that in R0 mice (p < 0.01) (Figure 2D).
Insulinogenic index was similar in C3H, R0 and R1 mice,




Number of mice analyzed 9 20
Body weight (g) 43.5 ± 1.6c 29.5 ± 0.5
Anal-nasal length (cm) 11.0 ± 0.1c 10.2 ± 0.1
BMI (g/cm2) 0.357 ± 0.007c 0.283 ± 0.005
Total fat (g) 3.451 ± 0.260c 1.023 ± 0.052
Epididymal fat (g) 1.578 ± 0.106c 0.509 ± 0.033
Retroperitoneal fat (g) 1.083 ± 0.120c 0.119 ± 0.009
Mesenteric fat (g) 0.789 ± 0.059c 0.395 ± 0.020
Total fat / body weight (%) 7.85 ± 0.34c 3.49 ± 0.18
Values are total number or mean ± SEM.
NSY, C3H-Chr 14NSY (R0), C3H.NSY-(D14Mit206-D14Mit5) (R1), and C3H.NSY-(D14Mit2
cp < 0.001). R1 and R2 mice were compared with R0 (dp < 0.05, ep < 0.01). R2 was cthe glucose-lowering effect of insulin was significantly
impaired in R1 compared to C3H mice (p < 0.01), but this
was not as severe as in R0 mice (p < 0.05) (Figure 2F).
Body weight in R1 mice was not significantly different
from that in C3H mice, as in the case of R0 mice. Fat-pad
weight and percentage fat-pad weight/body weight wereonsomic R0 and congenic R1 and R2 mice at 30 weeks
Consomic strain Congenic strains
R0 R1 R2
15 12 15
30.2 ± 0.6 30.8 ± 0.8 32.2 ± 0.6c,d
10.1 ± 0.1 10.1 ± 0.1 10.2 ± 0.1
0.294 ± 0.005 0.304 ± 0.005b 0.310 ± 0.005c,d
1.385 ± 0.100b 1.390 ± 0.088c 1.683 ± 0.095c,d,f
0.723 ± 0.052b 0.730 ± 0.058b 0.880 ± 0.051c,e
0.179 ± 0.018b 0.173 ± 0.013b 0.269 ± 0.019c,e,g
0.483 ± 0.033a 0.487 ± 0.025b 0.534 ± 0.029c
4.53 ± 0.26b 4.48 ± 0.22b 5.18 ± 0.21c,f
06-D14Mit186) (R2) mice were compared with C3H (ap < 0.05, bp < 0.01,
ompared with R1 (fp < 0.05, gp < 0.001).
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No significant differences were observed between R1 and
R0 mice (Table 1).
Phenotypic analysis of congenic R2 mice
Glucose tolerance in R2 mice was similar to that in R1 mice
(Figure 2B, C, D). Insulinogenic index in R2 mice was not
significantly different from that in C3H mice (Figure 2E).
The glucose-lowering effect of insulin during ITT was
significantly impaired in R2 compared with that in C3H
mice (p < 0.001) and R1 mice (p < 0.01) (Figure 2F).
R2 mice showed significantly higher body weight, BMI,
fat-pad weight and percentage fat-pad weight/body weight
than those in control C3H mice (Table 1). Body weight,
BMI and fat-pad weight were significantly higher in R2
mice than in R0 mice (Table 1). Fat-pad weight and per-
centage fat-pad weight/body weight in R2 mice were
significantly higher than those in R1 mice (Table 1).
Adipocytokines
Serum leptin level was significantly higher in NSY than
in C3H mice. R0, R1 and R2 mice showed significantly
higher leptin level than that in C3H mice (Figure 3A).
Leptin level in R0 and R1 mice was significantly
lower than that in NSY mice, while that in R2 mice
was not significantly different from that in NSY mice
(Figure 3A).
Serum adiponectin level in NSY mice was significantly
higher than that in C3H mice (Figure 3B), despite their
having a much higher body mass index and fat mass
(Table 1), which usually reduce serum adiponectin level.
Adiponectin level in R0, R1 and R2 mice was signifi-
cantly lower than that in C3H mice, with no significant
difference among R0, R1 and R2 mice (Figure 3B).
Since serum levels of leptin and adiponectin are known
to be affected by fat mass, we studied the correlation of
serum leptin and adiponectin levels with fat-pad weight
(Figure 3C, D). A significant correlation was observed
between leptin level and fat-pad weight in mice with
C3H background (R0, R1, R2 and C3H mice) (r = 0.78,
p < 0.0001). A significant correlation with a similar
slope was also observed in NSY mice (r = 0.75, p < 0.05),
but the regression line was shifted to the right (Figure 3C).
A significant negative correlation between adiponectin
level and fat-pad weight was observed in mice with
C3H background (R0, R1, R2 and C3H mice; r = −0.48,
p < 0.005), but not in NSY mice (r = 0.41, p = 0.28)
(Figure 3D).
Discussion
We previously mapped a QTL, Nidd2n, affecting diabetes-
related phenotypes in a broad segment of Chr 14 [6]. Sub-
sequent studies using consomic C3H-Chr 14NSY mice, in
which the entire NSY-Chr 14 was introgressed onto thegenetic background of control C3H mice, clearly demon-
strated that NSY-Chr 14 harbors a locus for diabetes and
insulin resistance without body weight gain [8]. To further
localize and characterize Nidd2n on Chr 14, we estab-
lished two novel congenic strains, in which limited seg-
ments of NSY-Chr 14 were introgressed onto control C3H
background genes. One congenic strain, termed R1, pos-
sessed the proximal half segment of NSY-Chr 14, and the
other congenic strain, termed R2, possessed a more lim-
ited segment of NSY-Chr 14 (Figure 1). By comparing the
phenotypes of congenic R1 and R2 mice with those of ori-
ginal C3H-Chr 14NSY consomic mice, termed R0, as well
as those of parental NSY and C3H mice, we found that
Nidd2n consisted of at least two components, one in the
proximal region and the other in the distal region of Chr
14. Since R2 mice, which possessed the most proximal
segment of NSY-Chr 14, showed significantly higher blood
glucose levels after glucose challenge than those in control
C3H mice, one component of Nidd2n affecting hypergly-
cemia is localized to this region. The fact that R1 mice,
which possessed a larger segment of proximal NSY-Chr
14, showed similar glucose levels to those in R2 mice, but
significantly lower glucose levels than those in consomic
R0 mice, suggests that a second component of Nidd2n
affecting hyperglycemia is localized to the distal segment
of NSY-Chr 14, which is possessed by R0, but not by R1.
We provisionally designated the former component
Nidd2.1n and the latter component Nidd2.2n (Figure 4).
In contrast to the consistently high post-challenge glu-
cose levels in all strains with NSY-Chr 14, namely R0,
R1 and R2, fasting glucose level in R1 and R2 mice was
completely different from that in R0 mice in that R1 and
R2 mice showed a significantly lower fasting glucose
level than that in C3H mice, while R0 mice showed a
significantly higher level than that in C3H mice, as in
the case of NSY mice. These data indicate that the gen-
etic control of fasting glucose and post-challenge glucose
is different, and that the distal segment of NSY-Chr 14
possessed by R0, but not by R1 and R2, harbors a locus
for fasting hyperglycemia. As discussed in the previous
section, this segment harbors Nidd2.2n, which increases
post-challenge glucose from the levels in R1 and R2
mice to the higher levels observed in R0 mice. Thus,
Nidd2.2n in the distal segment of NSY-Chr 14 affects
fasting as well as post-challenge hyperglycemia, while
Nidd2.1n in the proximal segment of NSY-Chr 14 affects
only post-challenge hyperglycemia, but not fasting hyper-
glycemia, and rather decreases the fasting glucose level.
Consistent with our previous observation in R0 conso-
mic mice [8], insulin secretion in response to glucose
loading was not impaired in either the R1 or R2 congenic
strain. In contrast, both R1 and R2 mice were insulin re-
sistant as shown by the decrease in the glucose-lowering






















Figure 3 Adipocytokines in NSY, C3H, C3H-Chr 14NSY (R0), C3H.NSY-(D14Mit206-D14Mit5) (R1) and C3H.NSY-(D14Mit206-D14Mit186) (R2)
mice. A. Serum leptin level in NSY (n = 9), C3H (n = 17), R0 (n = 15), R1 (n = 12) and R2 mice (n = 15). B. Serum adiponectin level in NSY (n = 9),
C3H (n = 11), R0 (n = 11), R1 (n = 11) and R2 mice (n = 11). C. Correlation between leptin and visceral fat-pad weight in mice with C3H background
(C3H, R0, R1, and R2 mice; n = 59; ○) and NSY mice (n = 9; ●). Lines indicate linear regression. D. Correlation between adiponectin level and visceral
fat-pad weight in mice with C3H background (C3H, R0, R1, and R2 mice; n = 44; open circles) and NSY mice (n = 9; closed circles). Lines indicate linear
regression. *p < 0.05, **p < 0.01, ***p < 0.001 vs. C3H. †p < 0.05, ††p < 0.01, †††p < 0.001 vs. NSY.
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mainly caused by insulin resistance, rather than impaired
insulin secretion, and that a locus for insulin resistance is
localized in the proximal segment of Chr 14 retained in


















Figure 4 Position of diabetes-related loci, Nidd2.1n, Nidd2.2n and Adp1n
phenotypes. Original Nidd2n is shown in black (significant linkage) and whiteaffecting hyperglycemia described above (Figure 4), sug-
gesting that Nidd2.1n is a locus for insulin resistance as
well as hyperglycemia.
Anatomical analysis revealed that phenotypes of R2
congenic mice are notably different from those of R0 andfter GTT BW Fat-pad resistance Leptin Adiponectin
se Obesity Insulin Adipocytokines
, on mouse chromosome 14 and their effect on diabetes-related
(suggestive linkage) boxes. ↑; increase, ↓; decrease.
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and adiposity in R0 and R1 mice, R2 mice showed sig-
nificantly greater body weight than R0 mice and greater
fat-pad weight than R0 and R1 mice (Table 1). These
data indicate that a locus that strongly increases adipos-
ity is located in the proximal segment of NSY-Chr 14
retained in R2 mice, and that a locus outside this region
of Chr 14 plays a role in the reduction of body weight
and adiposity. The former locus may well be the same
as Nidd2.1n for insulin resistance and hyperglycemia
discussed above. The latter locus, which is protective
against obesity and adiposity, is localized to the middle
segment of NSY-Chr 14 possessed by R1, but not by R2,
and is provisionally designated Adp1n for adiposity locus
1 in NSY (Figure 4). The NSY allele at Adp1n decreases
while the C3H allele increases fat-pad weight. Adp1n may
explain why R0 consomic mice in our previous study were
insulin resistant without body weight gain, in that insulin
resistance and adiposity were controlled by Nidd2.1n,
while adiposity was reduced and obesity was masked by
the effect of Adp1n. Mice with NSY alleles at both
Nidd2.1n and Adp1n, as in the case of R0 and R1, show
insulin resistance without body weight gain, while mice
with the NSY allele at Nidd2.1n, but with the C3H allele
at Adp1n, as in the case of R2, show insulin resistance
with obesity.
Although all three strains, R0, R1 and R2, showed
insulin resistance as compared with control C3H mice,
insulin resistance was significantly milder in R1 than in
R0 mice (Figure 2F), suggesting that a locus in the distal
segment of NSY-Chr 14 possessed by R0, but not by R1,
contributed to increased insulin resistance. These data
suggest that at least three loci on Chr 14 contribute to
insulin resistance: one in the proximal, another in the
middle and the other in the distal segment (Figure 4).
An NSY allele at a locus in the middle segment of Chr
14 contributed to the reduction of insulin resistance
observed in R1, while NSY alleles in the proximal and
distal segments contributed to worse insulin resistance.
The middle segment of NSY-Chr 14, where a locus to
reduce insulin resistance was mapped, overlaps with the
region where Adp1n, which decreases adiposity, was
mapped, and may well be the same locus. The NSY allele
at this locus decreases adiposity and improves insulin
sensitivity, as shown by the lower body weight, smaller
fat mass and better insulin sensitivity observed in R1
mice than in R2 mice. The proximal and distal segments
of NSY-Chr 14, where loci for insulin resistance were
mapped, overlap with the segments where Nidd2.1n and
Nidd2.2n, respectively, were mapped. R0 possesses an
insulin-resistance allele at two loci, Nidd2.1n and Nidd2.2n,
and an insulin-sensitivity allele at Adp1n in the middle
segment of Chr 14, while R1 mice possess an insulin-
resistance allele at Nidd2.1n and an insulin-sensitivityallele at Adp1n, leading to less severe insulin resistance
than that in R0 (Figure 4). Thus, the original Nidd2n,
which was mapped to a relatively broad region in the
middle portion of Chr 14 [6], is now dissected into mul-
tiple components: Nidd2.1n in the most proximal segment
of NSY-Chr 14, retained in R2 and contributing to hyper-
glycemia, insulin resistance and adiposity; Nidd2.2n in the
distal segment of NSY-Chr 14, retained in R0 but not in
R1, for insulin resistance and hyperglycemia; and Adp1n
in the middle segment of NSY-Chr 14, retained in R1 but
not in R2, reducing adiposity and improving insulin sen-
sitivity (Figure 4). The NSY alleles at Nidd2.1n and
Nidd2.2n worsen metabolic phenotypes, while the NSY
allele at Adp1n improves metabolic phenotypes by decreas-
ing fat mass and improving insulin sensitivity.
Adipocytokines are important mediators linking adiposity
with insulin resistance and metabolic abnormalities.
Common forms of obesity are characterized by ele-
vated circulating leptin [15]. Neither a high endogen-
ous leptin level nor treatment with exogenous leptin is
effective in ameliorating the most common form of
obesity, consistent with a state of leptin resistance [16].
NSY mice had an extremely high level of leptin (Figure 3A),
as was reported in a number of obesity models [17]. Leptin
level in R0, R1 and R2 mice was significantly higher than
that in control C3H mice (Figure 3A), indicating that
NSY-Chr 14 harbors a locus for leptin resistance. Leptin
level in R2 mice was as high as that in parental NSY mice,
with no significant difference between them, while that in
R0 and R1 was significantly lower than that in NSY mice.
These data suggest that a locus contributing to leptin re-
sistance is localized in the proximal segment of NSY-Chr
14 retained in R2. This region overlaps with the region for
Nidd2.1n, affecting adiposity, insulin resistance and hyper-
glycemia, and may well be the same locus. The NSY allele
at this locus appears to increase body weight and fat mass,
and cause leptin resistance and insulin resistance, leading
to hyperglycemia.
Since the serum level of leptin is known to be affected
by fat mass, we studied the correlation of serum leptin
level with fat-pad weight (Figure 3C). A significant correl-
ation was detected in mice with C3H background (R0, R1,
R2 and C3H mice) (Figure 3C, open circles). A significant
correlation was also observed in NSY mice (Figure 3C,
closed circles), but the regression line was markedly
shifted toward the right. These results suggest that
NSY-Chr 14 affected serum leptin level by increasing
fat-pad weight, and that the NSY genetic background
outside Chr 14 shifted the correlation between leptin
level and fat-pad weight toward a lower level relative to
fat-pad weight.
Studies of humans generally suggest that circulating
levels of most adipocytokines are elevated in individuals
with obesity. One exception is adiponectin, whose level
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against insulin resistance in vivo [19,20]. In the present
study, R0, R1 and R2 mice showed a markedly lower
level of adiponectin than that in C3H mice (Figure 3B),
indicating that NSY-Chr 14 decreases serum adiponectin
level, as observed in human obesity. The fact that serum
adiponectin level in R0, R1 and R2 mice was significantly
lower than that in C3H mice indicates that the proximal
region of NSY-Chr 14 retained in R2 contributed to the
decrease in serum adiponectin level. This locus may well
be the same as Nidd2.1n, which is associated with increased
fat mass, insulin resistance, leptin resistance and hypergly-
cemia. In contrast to the low adiponectin level observed in
R0, R1 and R2 mice, NSY mice showed a markedly higher
level of adiponectin than that in C3H mice (Figure 3B)
despite a much larger fat mass than that in C3H, R0, R1
and R2 mice (Table 1). A significant negative correlation
between fat-pad weight and adiponectin level was ob-
served in R0, R1, R2 and control C3H mice (Figure 3D),
as in the case of human obesity, suggesting that NSY-Chr
14 affected serum adiponectin level by increasing fat-pad
weight. In NSY mice, however, this correlation was com-
pletely lost (Figure 3D), indicating that the NSY genetic
background outside Chr 14 contributed to the increase in
serum adiponectin level and dysregulation of adiponectin
level relative to fat-pad weight. These data, together with
the data on leptin discussed above, suggest that NSY-Chr
14 affects adipocytokine level through changes in fat-pad
weight, as is observed in human obesity, while the genetic
background of NSY mice outside Chr 14 causes abnor-
mality of adipocytokine regulation in that leptin level is
shifted toward a lower level relative to fat-pad weight and
the correlation between adiponectin level and fat-pad
weight is completely lost.
The proximal region of Chr 14, where Nidd2.1n was
mapped in the present study, was previously shown to
be linked to diabetes and/or obesity in several other in-
dependent crosses [21-27]. The data in the present
study together with previous reports strongly suggest
the importance of the proximal region of Chr 14 in
conferring susceptibility to diabetes, insulin resistance
and fat accumulation common to several strains of
mice. In humans, a locus for waist-hip ratio has been
mapped to the syntenic region by GWAS study [1], and
Stabilin 1 (Stab1; 19.09 cM; which acts as a scavenger
receptor for acetylated low density lipoprotein) [28] is a
candidate gene in the region. Other candidate genes on
Chr 14 are a protein kinase C, delta gene (Prkcd;
18.82 cM; which has an important role in insulin receptor
signaling) [29-32], a pancreatic polypeptide receptor 1
gene (Ppyr1; 20.80 cM; a synonym of neuropeptide Y
receptor 4) [33], and a docking protein 2 (Dok2; 36.71 cM;
a member of the insulin receptor substrate-1 family of pro-
teins) [21,34]. Type 2 diabetes and obesity are complex,heterogeneous disorders with strong genetic components.
Identification of responsible genes and demonstration of
their effect on disease development remain a formidable
challenge. To identify causative variants, further studies
with sub-congenic strains, gene expression profiling in tar-
get organs, as well as gene-targeted approaches, such as
knockout and knock-in mice, are necessary [35].
Conclusions
The present study demonstrated that Nidd2n, a locus
for hyperglycemia and insulin resistance mapped to Chr
14 in our previous study, consisted of multiple compo-
nents (Figure 4). Nidd2.1n in the proximal segment of
NSY-Chr 14 increased body weight and fat-pad weight,
caused insulin resistance, and increased post-challenge
glucose levels, but decreased fasting glucose level. Nidd2.2n
in the distal segment of NSY-Chr 14 contributed to fasting
as well as post-challenge hyperglycemia and insulin resist-
ance. Adp1n in the middle segment of NSY-Chr 14 contrib-
uted to reduction in body weight and fat-pad mass and
better insulin sensitivity. It should be noted that this con-
clusion was drawn from the presumption that all QTLs act
in an additive fashion, and the possibility of non-additive
interaction among the loci cannot be excluded.
The congenic strains established in this study provide
powerful tools for investigating the pathological and
physiological consequences of individual susceptibility
genes for diabetes and obesity. Subsequent construction
of new sub-congenic strains and sequencing analysis
will lead to fine mapping and identification of causal
variants of responsible genes for Nidd2.1n, Nidd2.2n and
Adp1n. In addition, a congenic study with gene expression
profiling in target organs [36], i.e. adipose cells, liver, and
pancreatic islets) will help to detect causative genes in the
NSY mouse. Such studies are now underway [37].
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